Emergent BioSolutions (EBS) Misses Q4 EPS by 81c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.38 -0.95%
EPS Growth %: -31.3%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: -31.3%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.43), $0.81 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $148.7 million versus the consensus estimate of $237 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allison Transmission to Join S&P MidCap 400; Goodyear Tire & Rubber to Join S&P SmallCap 600
- Jefferies Upgrades Murphy USA (MUSA) to Buy
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
